{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:46:46Z","timestamp":1786985206715,"version":"build-2736575974"},"reference-count":266,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.bioorg.2021.105016","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T23:25:01Z","timestamp":1621898701000},"page":"105016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Potential drug development and therapeutic approaches for clinical intervention in COVID-19"],"prefix":"10.1016","volume":"114","author":[{"given":"Jayanta","family":"Dowarah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brilliant N.","family":"Marak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh Chand Singh","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ved Prakash","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7798","key":"10.1016\/j.bioorg.2021.105016_b0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"issue":"7798","key":"10.1016\/j.bioorg.2021.105016_b0010","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2021.105016_b0015","unstructured":"P.S. Masters, S. Perlman, Coronaviridae. Fields Virology, Eds Knipe DM, Howley PM; Lippincott Williams & Wilkins, Philadelphia, 2013."},{"issue":"10228","key":"10.1016\/j.bioorg.2021.105016_b0020","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(20)30557-2","article-title":"SARS-CoV-2 is an appropriate name for the new coronavirus","volume":"395","author":"Wu","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.bioorg.2021.105016_b0025","unstructured":"Coronavirus disease (COVID-19) https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019 (accessed Mar 11, 2021)."},{"issue":"11","key":"10.1016\/j.bioorg.2021.105016_b0030","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/v4113044","article-title":"Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies","volume":"4","author":"Geller","year":"2012","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b0035","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3181\/00379727-121-30734","article-title":"A new virus isolated from the human respiratory tract","volume":"121","author":"Hamre","year":"1966","journal-title":"Exp. Biol. Med."},{"issue":"4","key":"10.1016\/j.bioorg.2021.105016_b0040","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1073\/pnas.57.4.933","article-title":"Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease","volume":"57","author":"McIntosh","year":"1967","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.bioorg.2021.105016_b0045","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.drudis.2020.01.015","article-title":"Recent discovery and development of inhibitors targeting coronaviruses","volume":"25","author":"Pillaiyar","year":"2020","journal-title":"Drug Discovery Today"},{"issue":"19","key":"10.1016\/j.bioorg.2021.105016_b0050","doi-asserted-by":"crossref","first-page":"8913","DOI":"10.1128\/JVI.74.19.8913-8921.2000","article-title":"Neuroinvasion by human respiratory coronaviruses","volume":"74","author":"Arbour","year":"2000","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.bioorg.2021.105016_b0055","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1128\/JVI.73.4.3326-3337.1999","article-title":"Persistent infection of human oligodendrocytic and neuroglial cell lines by human coronavirus 229E","volume":"73","author":"Arbour","year":"1999","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b0060","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.virol.2006.01.049","article-title":"Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB\/C mice","volume":"349","author":"Jacomy","year":"2006","journal-title":"Virology"},{"issue":"8","key":"10.1016\/j.bioorg.2021.105016_b0065","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1086\/374222","article-title":"An outbreak of coronavirus OC43 respiratory infection in Normandy, France","volume":"36","author":"Vabret","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.bioorg.2021.105016_b0070","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1750-2659.2008.00049.x","article-title":"Human coronavirus NL63 infections in infants hospitalised with acute respiratory tract infections in South Africa","volume":"2","author":"Smuts","year":"2008","journal-title":"Influenza Other Respir Viruses"},{"issue":"12 Suppl","key":"10.1016\/j.bioorg.2021.105016_b0075","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1038\/nm1143","article-title":"Severe acute respiratory syndrome","volume":"10","author":"Peiris","year":"2004","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b0080","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1586\/14787210.5.2.245","article-title":"Identification of new human coronaviruses","volume":"5","author":"Pyrc","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"11","key":"10.1016\/j.bioorg.2021.105016_b0085","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/cmdc.202000223","article-title":"Drug development and medicinal chemistry efforts toward SARS-coronavirus and Covid-19 therapeutics","volume":"15","author":"Ghosh","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2021.105016_b0090","unstructured":"WHO | Update 49 - SARS case fatality ratio, incubation period https:\/\/www.who.int\/csr\/sars\/archive\/2003_05_07a\/en\/ (accessed Mar 11, 2021)."},{"issue":"26","key":"10.1016\/j.bioorg.2021.105016_b0095","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1303729","article-title":"Family cluster of middle east respiratory syndrome coronavirus infections","volume":"368","author":"Memish","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bioorg.2021.105016_b0100","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2105\/AJPH.2019.305186","article-title":"Risk factors for fatal middle east respiratory syndrome coronavirus infections in saudi arabia: analysis of the WHO line List, 2013\u20132018","volume":"109","author":"Rahman","year":"2019","journal-title":"Am J Public Health"},{"issue":"6","key":"10.1016\/j.bioorg.2021.105016_b0105","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3201\/eid2006.140299","article-title":"MERS coronaviruses in dromedary camels, Egypt","volume":"20","author":"Chu","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.bioorg.2021.105016_b0110","doi-asserted-by":"crossref","unstructured":"World Health Organization. Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease Is Suspected. Interim Guidance. Pediatr Med Rodz 2020, 16 (1), 9\u201326. https:\/\/doi.org\/10.15557\/PiMR.2020.0003.","DOI":"10.15557\/PiMR.2020.0003"},{"issue":"7","key":"10.1016\/j.bioorg.2021.105016_b0115","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.3390\/ijms21072657","article-title":"A review of SARS-CoV-2 and the ongoing clinical trials","volume":"21","author":"Tu","year":"2020","journal-title":"IJMS"},{"issue":"6","key":"10.1016\/j.bioorg.2021.105016_b0120","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses","volume":"24","author":"Su","year":"2016","journal-title":"Trends Microbiol."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105016_b0125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat Rev Microbiol"},{"issue":"9","key":"10.1016\/j.bioorg.2021.105016_b0130","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19","volume":"41","author":"Huang","year":"2020","journal-title":"Acta Pharmacol Sin"},{"issue":"9","key":"10.1016\/j.bioorg.2021.105016_b0135","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1128\/JVI.02232-10","article-title":"Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response","volume":"85","author":"Glowacka","year":"2011","journal-title":"J. Virol."},{"issue":"23","key":"10.1016\/j.bioorg.2021.105016_b0140","doi-asserted-by":"crossref","first-page":"12552","DOI":"10.1128\/JVI.01890-13","article-title":"Middle east respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2","volume":"87","author":"Shirato","year":"2013","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b0145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40779-020-00240-0","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak \u2013 an update on the Status","volume":"7","author":"Guo","year":"2020","journal-title":"Military Med Res"},{"key":"10.1016\/j.bioorg.2021.105016_b0150","doi-asserted-by":"crossref","unstructured":"P.S. Masters, The Molecular Biology of Coronaviruses. In: Advances in Virus Research; Elsevier, 2006; Vol. 66, pp 193\u2013292. https:\/\/doi.org\/10.1016\/S0065-3527(06)66005-3.","DOI":"10.1016\/S0065-3527(06)66005-3"},{"issue":"5","key":"10.1016\/j.bioorg.2021.105016_b0155","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.it.2020.03.007","article-title":"Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses","volume":"41","author":"Jiang","year":"2020","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bioorg.2021.105016_b0160","doi-asserted-by":"crossref","unstructured":"D.A. Brian, R.S. Baric, Coronavirus Genome Structure and Replication. In Coronavirus Replication and Reverse Genetics; Enjuanes, L., Ed.; Compans, R. W., Cooper, M. D., Honjo, T., Koprowski, H., Melchers, F., Oldstone, M. B. A., Olsnes, S., Potter, M., Vogt, P. K., Wagner, H., Series Eds.; Current Topics in Microbiology and Immunology; Springer Berlin Heidelberg: Berlin, Heidelberg, 2005; Vol. 287, pp 1\u201330. https:\/\/doi.org\/10.1007\/3-540-26765-4_1.","DOI":"10.1007\/3-540-26765-4_1"},{"key":"10.1016\/j.bioorg.2021.105016_b0165","doi-asserted-by":"crossref","unstructured":"A.R. Fehr, S. Perlman, Coronaviruses: An Overview of Their Replication and Pathogenesis. In: Coronaviruses; Maier, H. J., Bickerton, E., Britton, P., Eds.; Methods in Molecular Biology; Springer New York: New York, NY, 2015; Vol. 1282, pp 1\u201323. https:\/\/doi.org\/10.1007\/978-1-4939-2438-7_1.","DOI":"10.1007\/978-1-4939-2438-7_1"},{"issue":"6483","key":"10.1016\/j.bioorg.2021.105016_b0170","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-NCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b0175","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11684-020-0754-0","article-title":"Single-cell RNA-Seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-NCoV infection","volume":"14","author":"Zou","year":"2020","journal-title":"Front. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b0180","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.bioorg.2021.105016_b0185","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijid.2020.04.027","article-title":"Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-NCoV infection","volume":"96","author":"Zhang","year":"2020","journal-title":"Int. J. Infect. Diseases"},{"issue":"6","key":"10.1016\/j.bioorg.2021.105016_b0190","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.cell.2019.08.008","article-title":"Single-cell analysis of crohn\u2019s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy","volume":"178","author":"Martin","year":"2019","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bioorg.2021.105016_b0195","doi-asserted-by":"crossref","first-page":"2000688","DOI":"10.1183\/13993003.00688-2020","article-title":"ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19","volume":"55","author":"Leung","year":"2020","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.bioorg.2021.105016_b0200","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.bioorg.2021.105016_b0205","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1073\/pnas.2002589117","article-title":"Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells","volume":"117","author":"Matsuyama","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b0210","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bioorg.2021.105016_b0215","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-NCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.bioorg.2021.105016_b0220","unstructured":"B. Stephens, Opinion | The Story of Remdesivir. The New York Times. April 17, 2020."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105016_b0225","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1- f ][Triazin-4-Amino] adenine C -nucleoside (GS-5734) for the treatment of ebola and emerging viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J. Med. Chem."},{"issue":"396","key":"10.1016\/j.bioorg.2021.105016_b0230","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"20","key":"10.1016\/j.bioorg.2021.105016_b0235","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"7594","key":"10.1016\/j.bioorg.2021.105016_b0240","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b0245","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.bioorg.2021.105016_b0250","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"de Wit","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.bioorg.2021.105016_b0255","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bioorg.2021.105016_b0260","unstructured":"https:\/\/www.drugs.com\/monograph\/lopinavir-and-ritonavir.html 021251s052_021906s046lbl.Pdf. (accessed Mar 11, 2021)."},{"key":"10.1016\/j.bioorg.2021.105016_b0265","unstructured":"Lopinavir and Ritonavir Monograph for Professionals https:\/\/www.drugs.com\/monograph\/lopinavir-and-ritonavir.html (accessed Mar 11, 2021)."},{"issue":"12","key":"10.1016\/j.bioorg.2021.105016_b0270","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1128\/AAC.42.12.3218","article-title":"ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease","volume":"42","author":"Sham","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"27","key":"10.1016\/j.bioorg.2021.105016_b0275","doi-asserted-by":"crossref","first-page":"10012","DOI":"10.1073\/pnas.0403596101","article-title":"Small molecules targeting severe acute respiratory syndrome human coronavirus","volume":"101","author":"Wu","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b0280","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcv.2004.03.003","article-title":"In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds","volume":"31","author":"Chen","year":"2004","journal-title":"J. Clin. Virol."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105016_b0285","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"issue":"19","key":"10.1016\/j.bioorg.2021.105016_b0290","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105016_b0295","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2020.35.e79","article-title":"Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR","volume":"35","author":"Lim","year":"2020","journal-title":"J Korean Med Sci"},{"issue":"10238","key":"10.1016\/j.bioorg.2021.105016_b0300","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.bioorg.2021.105016_b0305","unstructured":"Oseltamivir Phosphate Monograph for Professionals https:\/\/www.drugs.com\/monograph\/oseltamivir-phosphate.html (accessed Jun 24, 2020)."},{"issue":"Suppl 1","key":"10.1016\/j.bioorg.2021.105016_b0310","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/irv.12047","article-title":"Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance","volume":"7","author":"McKimm-Breschkin","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.bioorg.2021.105016_b0315","unstructured":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus\u2013Infected Pneumonia in Wuhan, China | Critical Care Medicine | JAMA | JAMA Network https:\/\/jamanetwork.com\/journals\/jama\/article-abstract\/2761044 (accessed Jun 24, 2020)."},{"key":"10.1016\/j.bioorg.2021.105016_b0320","unstructured":"Ning, Q. An Open, Prospective\/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir\/Ritonavir) in the Treatment of 2019-NCoV Pneumonia.; Clinical trial registration NCT04255017; clinicaltrials.gov, 2020."},{"key":"10.1016\/j.bioorg.2021.105016_b0325","unstructured":"Kongsaengdao, D. S. A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir\/ Ritonavir Plus Oseltamivir Versus Darunavir\/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir\/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir \/ Ritonavir Versus Darunavir\/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19; Clinical trial registration NCT04303299; clinicaltrials.gov, 2020."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b0330","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2008.10.009","article-title":"Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol","volume":"81","author":"Leneva","year":"2009","journal-title":"Antiviral Res."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105016_b0335","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/JVI.02077-15","article-title":"The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses","volume":"90","author":"P\u00e9cheur","year":"2016","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.bioorg.2021.105016_b0340","first-page":"9","article-title":"Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures","volume":"53","author":"Khamitov","year":"2008","journal-title":"Vopr Virusol"},{"key":"10.1016\/j.bioorg.2021.105016_b0345","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: an update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b0350","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.002","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against corona virus disease 2019: a retrospective cohort study","volume":"81","author":"Deng","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.bioorg.2021.105016_b0355","article-title":"Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial","author":"Chen","year":"2020","journal-title":"Infectious Diseases (except HIV\/AIDS)"},{"issue":"3","key":"10.1016\/j.bioorg.2021.105016_b0360","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (Favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bioorg.2021.105016_b0365","doi-asserted-by":"crossref","unstructured":"Y. Furuta, T. Komeno, T. Nakamura, Favipiravir (T-705), a Broad Spectrum Inhibitor of Viral RNA Polymerase. In: Proceedings of the Japan Academy. Ser. B: Physical and Biological Sciences 2017, 93 (7), 449\u2013463. https:\/\/doi.org\/10.2183\/pjab.93.027.","DOI":"10.2183\/pjab.93.027"},{"key":"10.1016\/j.bioorg.2021.105016_b0370","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (Favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bioorg.2021.105016_b0375","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational ebola virus infection in a mouse model","volume":"104","author":"Smither","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bioorg.2021.105016_b0380","doi-asserted-by":"crossref","unstructured":"D. Sissoko, C. Laouenan, E. Folkesson, A.-B. M\u2019Lebing, A.-H. Beavogui, S. Baize, A.-M. Camara, P. Maes, S. Shepherd, C. Danel, S. Carazo, M.N. Conde, J.-L. Gala, G. Colin, H. Savini, J.A. Bore, F. Le Marcis, F.R. Koundouno, F. Petitjean, M.-C. Lamah, S. Diederich, A. Tounkara, G. Poelart, E. Berbain, J.-M. Dindart, S. Duraffour, A. Lefevre, T. Leno, O. Peyrouset, L. Irenge, N. Bangoura, R. Palich, J. Hinzmann, A. Kraus, T.S. Barry, S. Berette, A. Bongono, M.S. Camara, V. Chanfreau Munoz, L. Doumbouya, Souley Harouna, P.M. Kighoma, F.R. Koundouno, R\u00e9n\u00e9 Lolamou, C.M. Loua, V. Massala, K. Moumouni, C. Provost, N. Samake, C. Sekou, A. Soumah, I. Arnould, M.S. Komano, L. Gustin, C. Berutto, D. Camara, F.S. Camara, J. Colpaert, L. Delamou, L. Jansson, E. Kourouma, M. Loua, K. Malme, E. Manfrin, A. Maomou, A. Milinouno, S. Ombelet, A.Y. Sidiboun, I. Verreckt, P. Yombouno, A. Bocquin, C. Carbonnelle, T. Carmoi, P. Frange, S. Mely, V.-K. Nguyen, D. Pannetier, A.-M. Taburet, J.-M. Treluyer, J. Kolie, R. Moh, M.C. Gonzalez, E. Kuisma, B. Liedigk, D. Ngabo, M. Rudolf, R. Thom, R. Kerber, M. Gabriel, A. Di Caro, R. W\u00f6lfel, J. Badir, M. Bentahir, Y. Deccache, C. Dumont, J.-F. Durant, K. El Bakkouri, M. Gasasira Uwamahoro, B. Smits, N. Toufik, S. Van Cauwenberghe, K. Ezzedine, E. Dortenzio, L. Pizarro, A. Etienne, J. Guedj, A. Fizet, E. Barte de Sainte Fare, B. Murgue, T. Tran-Minh, C. Rapp, P. Piguet, M. Poncin, B. Draguez, T. Allaford Duverger, S. Barbe, G. Baret, I. Defourny, M. Carroll, H. Raoul, A. Augier, S.P. Eholie, Y. Yazdanpanah, C. Levy-Marchal, A. Antierrens, M. Van Herp, S. G\u00fcnther, X. de Lamballerie, S. Ke\u00efta, F. Mentre, X. Anglaret, D. Malvy, JIKI Study Group. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea, PLoS Med 13 (3) (2016) e1001967. https:\/\/doi.org\/10.1371\/journal.pmed.1001967.","DOI":"10.1371\/journal.pmed.1001967"},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b0385","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1038\/s41598-018-25780-3","article-title":"Favipiravir (T-705) protects against nipah virus infection in the hamster model","volume":"8","author":"Dawes","year":"2018","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105016_b0390","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering"},{"issue":"10","key":"10.1016\/j.bioorg.2021.105016_b0395","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.eng.2020.06.011","article-title":"The efficacy and safety of triazavirin for COVID-19: a trial protocol","volume":"6","author":"Wu","year":"2020","journal-title":"Engineering"},{"issue":"5","key":"10.1016\/j.bioorg.2021.105016_b0400","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1128\/AAC.01186-09","article-title":"Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication","volume":"54","author":"Karpenko","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2021.105016_b0405","first-page":"3","article-title":"Investigation of Triazavirin antiviral activity against tick-borne encephalitis pathogen in cell culture","volume":"59","author":"Loginova","year":"2014","journal-title":"Antibiot Khimioter"},{"issue":"5\u20136","key":"10.1016\/j.bioorg.2021.105016_b0410","first-page":"8","article-title":"Investigation of prophylactic efficacy of triazavirin against experimental forest- spring encephalitis on albino mice","volume":"60","author":"Loginova","year":"2015","journal-title":"Antibiot Khimioter"},{"key":"10.1016\/j.bioorg.2021.105016_b0415","doi-asserted-by":"crossref","unstructured":"D.E. Gordon, G.M. Jang, M. Bouhaddou, J. Xu, K. Obernier, M.J. O\u2019Meara, J.Z. Guo, D.L. Swaney, T.A. Tummino, R. H\u00fcttenhain, R.M. Kaake, A.L. Richards, B. Tutuncuoglu, H. Foussard, J. Batra, K. Haas, M. Modak, M. Kim, P. Haas, B.J. Polacco, H. Braberg, J.M. Fabius, M. Eckhardt, M. Soucheray, M.J. Bennett, M. Cakir, M.J. McGregor, Q. Li, Z.Z.C. Naing, Y. Zhou, S. Peng, I.T. Kirby, J.E. Melnyk, J.S. Chorba, K. Lou, S.A. Dai, W. Shen, Y. Shi, Z. Zhang, I. Barrio-Hernandez, D. Memon, C. Hernandez-Armenta, C.J.P. Mathy, T. Perica, K.B. Pilla, S.J. Ganesan, D.J. Saltzberg, R. Ramachandran, X. Liu, S.B. Rosenthal, L. Calviello, S. Venkataramanan, Y. Lin, S.A. Wankowicz, M. Bohn, R. Trenker, J.M. Young, D. Cavero, J. Hiatt, T. Roth, U. Rathore, A. Subramanian, J. Noack, M. Hubert, F. Roesch, T. Vallet, B. Meyer, K.M. White, L. Miorin, D. Agard, M. Emerman, D. Ruggero, A. Garc\u00eda-Sastre, N. Jura, M. von Zastrow, J. Taunton, O. Schwartz, M. Vignuzzi, C. d\u2019Enfert, S. Mukherjee, M. Jacobson, H.S. Malik, D.G. Fujimori, T. Ideker, C.S. Craik, S. Floor, J.S. Fraser, J. Gross, A. Sali, T. Kortemme, P. Beltrao, K. Shokat, B.K. Shoichet, N.J. Krogan, Human protein-protein interaction map reveals drug targets and potential drug-repurposing. Systems Biology; 2020. https:\/\/doi.org\/10.1101\/2020.03.22.002386.","DOI":"10.1038\/s41586-020-2286-9"},{"issue":"5","key":"10.1016\/j.bioorg.2021.105016_b0420","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses \u2014 drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105016_b0425","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.cmi.2016.08.025","article-title":"Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy","volume":"22","author":"Dustin","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105016_b0430","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s40265-014-0247-z","article-title":"Sofosbuvir: a review of its use in patients with chronic hepatitis C","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2021.105016_b0435","doi-asserted-by":"crossref","unstructured":"C.S. de Freitas, L.M. Higa, C.Q. Sacramento, A.C. Ferreira, P.A. Reis, R. Delvecchio, F.L. Monteiro, G. Barbosa-Lima, H. James Westgarth, Y.R. Vieira, M. Mattos, N. Rocha, L.V.B. Hoelz, R.P.P. Leme, M.M. Bastos, L. Rodrigues, G. O., M. Lopes, C. E., C.M.Queiroz-Junior, C.X. Lima, V.V. Costa, M.M. Teixeira, F.A. Bozza, P.T. Bozza, N. Boechat, A. Tanuri, T.M.L. Souza, Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo. PLoS Negl Trop Dis 13 (1) (2019) e0007072. https:\/\/doi.org\/10.1371\/journal.pntd.0007072.","DOI":"10.1371\/journal.pntd.0007072"},{"key":"10.1016\/j.bioorg.2021.105016_b0440","doi-asserted-by":"crossref","unstructured":"A.C. Ferreira, P.A. Reis, C.S. de Freitas, C.Q. Sacramento, L. Villas B\u00f4as Hoelz, M.M. Bastos, M. Mattos, N. Rocha, I. Gomes de Azevedo Quintanilha, C. da Silva Gouveia Pedrosa, L. Rocha Quintino Souza, E. Correia Loiola, P. Trindade, Y. Rangel Vieira, G. Barbosa-Lima, H.C. de Castro Faria Neto, N. Boechat, S.K. Rehen, K. Br\u00fcning, F.A. Bozza, P.T. Bozza, T.M.L. Souza, Beyond Members of the Flaviviridae Family, Sofosbuvir Also Inhibits Chikungunya Virus Replication. Antimicrob Agents Chemother 63 (2) (2018) e01389-18. https:\/\/doi.org\/10.1128\/AAC.01389-18.","DOI":"10.1128\/AAC.01389-18"},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b0445","doi-asserted-by":"crossref","first-page":"9409","DOI":"10.1038\/s41598-017-09797-8","article-title":"Sofosbuvir protects zika virus-infected mice from mortality, preventing short- and long-term sequelae","volume":"7","author":"Ferreira","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b0450","doi-asserted-by":"crossref","first-page":"40920","DOI":"10.1038\/srep40920","article-title":"The clinically approved antiviral drug sofosbuvir inhibits zika virus replication","volume":"7","author":"Sacramento","year":"2017","journal-title":"Sci. Rep."},{"issue":"6492","key":"10.1016\/j.bioorg.2021.105016_b0455","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2021.105016_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2021.105016_b0465","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-020-02355-3","article-title":"SARS-CoV-2 RNA polymerase as target for antiviral therapy","author":"Buonaguro","year":"2020","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b0470","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/jac\/dkaa418","article-title":"Sofosbuvir\/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis","volume":"76","author":"Simmons","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bioorg.2021.105016_b0475","unstructured":"BioCryst | Oral Drugs for Viruses | Galidesivir https:\/\/www.biocryst.com\/our-pipeline\/galidesivir\/ (accessed Mar 10, 2021)."},{"key":"10.1016\/j.bioorg.2021.105016_b0480","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2018.05.013","article-title":"Galidesivir limits rift valley fever virus infection and disease in syrian golden hamsters","volume":"156","author":"Westover","year":"2018","journal-title":"Antiviral Res."},{"issue":"12","key":"10.1016\/j.bioorg.2021.105016_b0485","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1128\/AAC.00699-08","article-title":"Preclinical characteristics of the hepatitis C Virus NS3\/4A protease inhibitor ITMN-191 (R7227)","volume":"52","author":"Seiwert","year":"2008","journal-title":"AAC"},{"issue":"48","key":"10.1016\/j.bioorg.2021.105016_b0490","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023357","article-title":"First clinical study using HCV Protease inhibitor danoprevir to treat COVID-19 patients","volume":"99","author":"Chen","year":"2020","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.bioorg.2021.105016_b0495","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/10408363.2017.1313190","article-title":"Prediction of therapy response in ovarian cancer: where are we now?","volume":"54","author":"El Bairi","year":"2017","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.bioorg.2021.105016_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bioorg.2021.105016_b0505","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2020.09.014","article-title":"Repurposing anticancer drugs for the management of COVID-19","volume":"141","author":"El Bairi","year":"2020","journal-title":"Eur. J. Can."},{"key":"10.1016\/j.bioorg.2021.105016_b0510","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.2147\/DDDT.S282252","article-title":"Repurposing anti-cancer drugs for COVID-19 treatment","volume":"14","author":"Borcherding","year":"2020","journal-title":"DDDT"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b0515","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19","volume":"383","author":"Ackermann","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bioorg.2021.105016_b0520","doi-asserted-by":"crossref","unstructured":"Ajayi, S.; Becker, H.; Reinhardt, H.; Engelhardt, M.; Zeiser, R.; von Bubnoff, N.; W\u00e4sch, R. Ruxolitinib. In Small Molecules in Hematology; Martens, U. M., Ed.; Recent Results in Cancer Research; Springer International Publishing: Cham, 2018; Vol. 212, pp 119\u2013132. https:\/\/doi.org\/10.1007\/978-3-319-91439-8_6.","DOI":"10.1007\/978-3-319-91439-8_6"},{"issue":"3","key":"10.1016\/j.bioorg.2021.105016_b0525","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4161\/jkst.19918","article-title":"Infection-induced IL-10 and JAK-STAT: a review of the molecular circuitry controlling immune hyperactivity in response to pathogenic microbes","volume":"1","author":"Carey","year":"2012","journal-title":"JAK-STAT"},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b0530","first-page":"1","article-title":"Toremifene for breast cancer: a review of 20 Years of data","volume":"14","author":"Vogel","year":"2014","journal-title":"Clin. Breast Can."},{"issue":"7610","key":"10.1016\/j.bioorg.2021.105016_b0535","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nature18615","article-title":"Toremifene interacts with and destabilizes the ebola virus glycoprotein","volume":"535","author":"Zhao","year":"2016","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.bioorg.2021.105016_b0540","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s40265-017-0830-1","article-title":"Middle east respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies","volume":"77","author":"Dyall","year":"2017","journal-title":"Drugs"},{"issue":"190","key":"10.1016\/j.bioorg.2021.105016_b0545","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005471","article-title":"FDA-approved selective estrogen receptor modulators inhibit ebola virus infection","volume":"5","author":"Johansen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioorg.2021.105016_b0550","doi-asserted-by":"crossref","unstructured":"Martin, W. R.; Cheng, F. Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2; preprint; 2020. https:\/\/doi.org\/10.26434\/chemrxiv.12431966.v1.","DOI":"10.26434\/chemrxiv.12431966.v1"},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b0555","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-NCoV\/SARS-CoV-2","volume":"6","author":"Zhou","year":"2020","journal-title":"Cell Discov"},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b0560","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.antiviral.2011.02.008","article-title":"Emodin inhibits current through SARS-associated coronavirus 3a protein","volume":"90","author":"Schwarz","year":"2011","journal-title":"Antiviral Res."},{"issue":"23","key":"10.1016\/j.bioorg.2021.105016_b0565","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1021\/acs.chemrev.6b00209","article-title":"Metabolism, biochemical actions, and chemical synthesis of anticancer nucleosides, nucleotides, and base analogs","volume":"116","author":"Shelton","year":"2016","journal-title":"Chem. Rev."},{"issue":"9","key":"10.1016\/j.bioorg.2021.105016_b0570","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/jjco\/hyi147","article-title":"An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancer","volume":"35","author":"Sakamoto","year":"2005","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b0575","first-page":"77","article-title":"Postoperative adjuvant use of carmofur for early breast cancer","volume":"49","author":"Morimoto","year":"2003","journal-title":"Osaka City Med. J."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105016_b0580","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00000421-199012000-00005","article-title":"Oral carmofur in advanced gastrointestinal cancer","volume":"13","author":"Gr\u00f6hn","year":"1990","journal-title":"Am. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b0585","first-page":"295","article-title":"Study on effectiveness of carmofur (Mifurol) in urogenital carcinoma, especially bladder cancer, as a post-operative adjuvant chemotherapeutic agent","volume":"33","author":"Nishio","year":"1987","journal-title":"Hinyokika Kiyo"},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b0590","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/srep01035","article-title":"Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity","volume":"3","author":"Realini","year":"2013","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105016_b0595","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41594-020-0440-6","article-title":"Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur","volume":"27","author":"Jin","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"19","key":"10.1016\/j.bioorg.2021.105016_b0600","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1158\/0008-5472.CAN-19-1167","article-title":"Recent advances targeting CCR5 for cancer and Its role in immuno-oncology","volume":"79","author":"Jiao","year":"2019","journal-title":"Can Res"},{"key":"10.1016\/j.bioorg.2021.105016_b0605","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008439.pub3","article-title":"Humanized PA14 (a Monoclonal CCR5 Antibody) for Treatment of People with HIV Infection","author":"Li","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.bioorg.2021.105016_b0610","doi-asserted-by":"crossref","unstructured":"B. Pattterson, H. Seetthamraju, K. Dhody, M. Corley, K. Kazempour, J. Lalezari, A. Pang, C.Sugai, E. Francisco, A. Pise, H. Rodrigues, M. Ryou, H. Wu, G. Webb, B. Park, S. Kelly, N.Pourhassan, A. Lelic, L. Kdouh, M. Herrera, E. Hall, E. Aklin, L. Ndhlovu, J. Sacha, Disruption of the CCL5\/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19; preprint; In Review, 2020. https:\/\/doi.org\/10.21203\/rs.3.rs-26517\/v1.","DOI":"10.21203\/rs.3.rs-26517\/v1"},{"issue":"13","key":"10.1016\/j.bioorg.2021.105016_b0615","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s40265-019-01188-9","article-title":"Selinexor: first global approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2021.105016_b0620","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.semcancer.2014.03.002","article-title":"Atomic basis of CRM1-cargo recognition, release and inhibition","volume":"27","author":"Fung","year":"2014","journal-title":"Semin. Can. Biol."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105016_b0625","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.drudis.2020.06.014","article-title":"Exportin 1 inhibition as antiviral therapy","volume":"25","author":"Uddin","year":"2020","journal-title":"Drug Disc. Today"},{"issue":"11","key":"10.1016\/j.bioorg.2021.105016_b0630","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1021\/acs.jmedchem.0c00182","article-title":"Design of development candidate EFT226, a first in class inhibitor of eukaryotic initiation factor 4A RNA helicase","volume":"63","author":"Ernst","year":"2020","journal-title":"J. Med. Chem."},{"issue":"Supplement 1","key":"10.1016\/j.bioorg.2021.105016_b0635","article-title":"Preclinical evaluation of EFT226, a novel, potent and selective EIF4A inhibitor with anti-tumor activity in B-cell malignancies","volume":"130","author":"Thompson","year":"2017","journal-title":"Blood"},{"issue":"7816","key":"10.1016\/j.bioorg.2021.105016_b0640","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2021.105016_b0645","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.virusres.2019.02.011","article-title":"Drug repurposing for new, efficient, broad spectrum antivirals","volume":"264","author":"Garc\u00eda-Serradilla","year":"2019","journal-title":"Virus Res."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b0650","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jac\/dkv363","article-title":"Inhibition of herpes simplex virus Type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1","volume":"71","author":"Badia","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.bioorg.2021.105016_b0655","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1172\/JCI89857","article-title":"Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects","volume":"127","author":"Bekerman","year":"2017","journal-title":"J. Clin. Investigat."},{"issue":"4","key":"10.1016\/j.bioorg.2021.105016_b0660","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.chembiol.2016.03.010","article-title":"GNF-2 inhibits dengue virus by targeting Abl kinases and the viral E protein","volume":"23","author":"Clark","year":"2016","journal-title":"Cell Chem. Biol."},{"issue":"8","key":"10.1016\/j.bioorg.2021.105016_b0665","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of middle east respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b0670","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1128\/AAC.03659-14","article-title":"Antiviral potential of ERK\/MAPK and PI3K\/AKT\/MTOR signaling modulation for middle east respiratory syndrome coronavirus infection as identified by temporal kinome analysis","volume":"59","author":"Kindrachuk","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.bioorg.2021.105016_b0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002845","article-title":"Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly","volume":"8","author":"Neveu","year":"2012","journal-title":"PLoS Pathog"},{"issue":"5","key":"10.1016\/j.bioorg.2021.105016_b0680","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1099\/jgv.0.001047","article-title":"Coronavirus S protein-induced fusion is blocked prior to hemifusion by abl kinase inhibitors","volume":"99","author":"Sisk","year":"2018","journal-title":"J. Gen. Virol."},{"issue":"19","key":"10.1016\/j.bioorg.2021.105016_b0685","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.1128\/JVI.01429-16","article-title":"Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion","volume":"90","author":"Coleman","year":"2016","journal-title":"J. Virol."},{"issue":"10224","key":"10.1016\/j.bioorg.2021.105016_b0690","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/j.bioorg.2021.105016_b0695","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1038\/s41375-020-01045-9","article-title":"Imatinib is not a potent anti-SARS-CoV-2 drug","volume":"34","author":"Zhao","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2021.105016_b0700","unstructured":"Duvelisib Monograph for Professionals https:\/\/www.drugs.com\/monograph\/duvelisib.html (accessed Mar 10, 2021)."},{"key":"10.1016\/j.bioorg.2021.105016_b0705","doi-asserted-by":"crossref","first-page":"2016061","DOI":"10.4084\/mjhid.2016.061","article-title":"Novel drugs in follicular lymphoma","volume":"8","author":"Rossi","year":"2016","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.bioorg.2021.105016_b0710","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cca.2020.06.017","article-title":"Cytokine storm induced by SARS-CoV-2","volume":"509","author":"Song","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bioorg.2021.105016_b0715","unstructured":"Study Aims to Evaluate Duvelisib in Reducing Lung Inflammation in Severe COVID-19 Cases https:\/\/www.oncnursingnews.com\/view\/study-aims-to-evaluate-duvelisib-in-reducing-lung-inflammation-in-severe-COVID-19-cases (accessed Mar 10, 2021)."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b0720","doi-asserted-by":"crossref","first-page":"L52","DOI":"10.1152\/ajplung.00047.2018","article-title":"Inhibiting Bruton\u2019s tyrosine kinase rescues mice from lethal influenza-induced acute lung injury","volume":"315","author":"Florence","year":"2018","journal-title":"Am. J. Physiol.-Lung Cell. Mol. Physiol."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105016_b0725","doi-asserted-by":"crossref","first-page":"L435","DOI":"10.1152\/ajplung.00234.2013","article-title":"Silencing Bruton\u2019s Tyrosine kinase in alveolar neutrophils protects mice from LPS\/immune complex-induced acute lung injury","volume":"307","author":"Krupa","year":"2014","journal-title":"Am. J. Physiol.-Lung Cell. Mol. Physiol."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b0730","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s12013-014-0050-1","article-title":"Knockdown of Burton\u2019s tyrosine kinase confers potent protection against sepsis-induced acute lung injury","volume":"70","author":"Zhou","year":"2014","journal-title":"Cell Biochem. Biophys."},{"issue":"16","key":"10.1016\/j.bioorg.2021.105016_b0735","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","article-title":"Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of bruton\u2019s tyrosine kinase","volume":"26","author":"Song","year":"2020","journal-title":"Clin. Can. Res."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b0740","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","article-title":"Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor","volume":"9","author":"Wu","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"21","key":"10.1016\/j.bioorg.2021.105016_b0745","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1182\/blood.2020006288","article-title":"The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19\u2013infected patients","volume":"135","author":"Treon","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2021.105016_b0750","doi-asserted-by":"crossref","unstructured":"C.S. Lewis, C. Voelkel-Johnson, C.D. Smith, Targeting sphingosine kinases for the treatment of cancer, in: Advances in Cancer Research; Elsevier, 2018; Vol. 140, pp 295\u2013325. https:\/\/doi.org\/10.1016\/bs.acr.2018.04.015.","DOI":"10.1016\/bs.acr.2018.04.015"},{"key":"10.1016\/j.bioorg.2021.105016_b0755","unstructured":"Opaganib - COVID-19 | Opaganib (Yeliva\u00ae) | Development Pipeline | Products | RedHill https:\/\/www.redhillbio.com\/opaganibCOVID-19 (accessed Mar 11, 2021)."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b0760","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/emi.2015.61","article-title":"Sphingosine kinase 2 Is a chikungunya virus host factor co-localized with the viral replication complex","volume":"4","author":"Reid","year":"2015","journal-title":"Emerging Microbes Infect."},{"issue":"7","key":"10.1016\/j.bioorg.2021.105016_b0765","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102314","article-title":"Sphingosine kinase-2 maintains viral latency and survival for KSHV-infected endothelial cells","volume":"9","author":"Dai","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bioorg.2021.105016_b0770","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.antiviral.2018.08.010","article-title":"Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice","volume":"158","author":"Xia","year":"2018","journal-title":"Antiviral Res."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105016_b0775","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/thoraxjnl-2018-212378","article-title":"Pseudomonas Aeruginosa stimulates nuclear sphingosine-1-phosphate generation and epigenetic regulation of lung inflammatory injury","volume":"74","author":"Ebenezer","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.bioorg.2021.105016_b0780","doi-asserted-by":"crossref","unstructured":"S. Bittmann, COVID 19: Camostat and The Role of Serine Protease Entry Inhibitor TMPRSS2. J Regen Biol Med 2020. https:\/\/doi.org\/10.37191\/Mapsci-2582-385X-2(2)-020.","DOI":"10.37191\/Mapsci-2582-385X-2(2)-020"},{"issue":"8","key":"10.1016\/j.bioorg.2021.105016_b0785","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s11739-020-02345-9","article-title":"Camostat mesilate therapy for COVID-19","volume":"15","author":"Uno","year":"2020","journal-title":"Int. Emerg Med."},{"issue":"11","key":"10.1016\/j.bioorg.2021.105016_b0790","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1128\/AAC.01043-16","article-title":"Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus s protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay","volume":"60","author":"Yamamoto","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b0795","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b0800","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2183\/pjab.87.13","article-title":"\u2018Wonder Drug\u2019 from Japan: the human use perspective","volume":"87","author":"Crump","year":"2011","journal-title":"Proc. Jpn. Acad., Ser. B"},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b0805","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJM199507063330105","article-title":"The treatment of scabies with ivermectin","volume":"333","author":"Meinking","year":"1995","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bioorg.2021.105016_b0810","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1042\/BJ20120150","article-title":"Ivermectin Is a specific inhibitor of importin \u03b1\/\u03b2-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus","volume":"443","author":"Wagstaff","year":"2012","journal-title":"Biochem. J"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b0815","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/1087057110390360","article-title":"An alphascreen \u00ae -based assay for high-throughput screening for specific inhibitors of nuclear import","volume":"16","author":"Wagstaff","year":"2011","journal-title":"J Biomol Screen"},{"issue":"3","key":"10.1016\/j.bioorg.2021.105016_b0820","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.antiviral.2013.06.002","article-title":"Nuclear localization of dengue virus (DENV) 1\u20134 non-structural protein 5; protection against All 4 DENV serotypes by the inhibitor ivermectin","volume":"99","author":"Tay","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bioorg.2021.105016_b0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104760","article-title":"The broad spectrum antiviral ivermectin targets the host nuclear transport importin \u03b1\/\u03b21 heterodimer","volume":"177","author":"Yang","year":"2020","journal-title":"Antiviral Res."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105016_b0830","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.antiviral.2013.10.004","article-title":"Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce venezuelan equine encephalitis virus replication","volume":"100","author":"Lundberg","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bioorg.2021.105016_b0835","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.antiviral.2018.09.010","article-title":"Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo","volume":"159","author":"Lv","year":"2018","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bioorg.2021.105016_b0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bioorg.2021.105016_b0845","first-page":"ddr.21757","article-title":"Step toward repurposing drug discovery for COVID -19 therapeutics through in silico approach","author":"Marak","year":"2020","journal-title":"Drug Dev Res"},{"issue":"3","key":"10.1016\/j.bioorg.2021.105016_b0850","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0002-9378(16)44537-0","article-title":"Treatment of hospitalized patients with acute pelvic inflammatory disease: comparison of cefotetan plus doxycycline and cefoxitin plus doxycycline","volume":"158","author":"Sweet","year":"1988","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b0855","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/00016347809155893","article-title":"Doxycycline (Vibramycin\u00ae) in pelvic inflammatory disease","volume":"57","author":"Gj\u00f8nn\u00e6ss","year":"1978","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"8","key":"10.1016\/j.bioorg.2021.105016_b0860","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00417-005-0212-3","article-title":"Tear Fluid levels of MMP-8 are elevated in ocular rosacea\u2014treatment effect of oral doxycycline","volume":"244","author":"M\u00e4\u00e4tt\u00e4","year":"2006","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmo"},{"issue":"6","key":"10.1016\/j.bioorg.2021.105016_b0865","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.mcna.2008.06.002","article-title":"Emerging and re-emerging tick-transmitted rickettsial and ehrlichial infections","volume":"92","author":"Walker","year":"2008","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.bioorg.2021.105016_b0870","unstructured":"Doxycycline: \u201cNew\u201d treatment of choice for genital chlamydia infections | British Columbia Medical Journal https:\/\/bcmj.org\/bccdc\/doxycycline-new-treatment-choice-genital-chlamydia-infections (accessed Mar 10, 2021)."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105016_b0875","first-page":"431","article-title":"Pharmacology and toxicology of doxycycline","volume":"30","author":"Riond","year":"1988","journal-title":"Vet Hum Toxicol"},{"issue":"11","key":"10.1016\/j.bioorg.2021.105016_b0880","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1128\/JCM.01498-13","article-title":"Pharmacodynamics of doxycycline and tetracycline against staphylococcus pseudintermedius: proposal of canine-specific breakpoints for doxycycline","volume":"51","author":"Maaland","year":"2013","journal-title":"J. Clin. Microbiol."},{"issue":"4","key":"10.1016\/j.bioorg.2021.105016_b0885","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4269\/ajtmh.2011.10-0285","article-title":"Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis","volume":"84","author":"Magill","year":"2011","journal-title":"Am. J. Tropical Med. Hyg."},{"issue":"4","key":"10.1016\/j.bioorg.2021.105016_b0890","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00430-002-0174-6","article-title":"Doxycycline as a novel strategy against bancroftian filariasis? Depletion of wolbachia endosymbionts from wuchereria bancrofti and stop of microfilaria production","volume":"192","author":"Hoerauf","year":"2003","journal-title":"Med. Microbiol. Immunol."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105016_b0895","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000428","article-title":"Combinatorial computational approaches to identify tetracycline derivatives as flavivirus inhibitors","volume":"2","author":"Yang","year":"2007","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.bioorg.2021.105016_b0900","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126360","article-title":"A combination of doxycycline and ribavirin alleviated chikungunya infection","volume":"10","author":"Rothan","year":"2015","journal-title":"PLoS ONE"},{"issue":"10229","key":"10.1016\/j.bioorg.2021.105016_b0905","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.bioorg.2021.105016_b0910","article-title":"Is It prime time to consider a clinical trial of doxycycline for the management of COVID-19?","author":"Milionis","year":"2020","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.bioorg.2021.105016_b0915","doi-asserted-by":"crossref","unstructured":"A.H.H.Bakheit, B.M.H. Al-Hadiya, A.A. Abd-Elgalil, Azithromycin, in: Profiles of Drug Substances, Excipients and Related Methodology; Elsevier, 2014; Vol. 39, pp 1\u201340. https:\/\/doi.org\/10.1016\/B978-0-12-800173-8.00001-5.","DOI":"10.1016\/B978-0-12-800173-8.00001-5"},{"key":"10.1016\/j.bioorg.2021.105016_b0920","unstructured":"050710s043,050711s040,050784s027lbl.Pdf."},{"issue":"4","key":"10.1016\/j.bioorg.2021.105016_b0925","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.bbrc.2019.11.065","article-title":"Combinatorial screening of a Panel of FDA-approved drugs identifies several candidates with anti-ebola activities","volume":"522","author":"Du","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"12","key":"10.1016\/j.bioorg.2021.105016_b0930","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00394-19","article-title":"Azithromycin protects against zika virus infection by upregulating virus-induced type I and III interferon responses","volume":"63","author":"Li","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.bioorg.2021.105016_b0935","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41429-019-0204-x","article-title":"Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)Pdm09 virus infection by interfering with virus internalization process","volume":"72","author":"Tran","year":"2019","journal-title":"J. Antibiot."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105016_b0940","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/ppul.23956","article-title":"Role of prophylactic azithromycin to reduce airway inflammation and mortality in a RSV mouse infection model","volume":"53","author":"Mosquera","year":"2018","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.bioorg.2021.105016_b0945","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jaci.2014.10.001","article-title":"Randomized trial to evaluate azithromycin\u2019s effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis","volume":"135","author":"Beigelman","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.bioorg.2021.105016_b0950","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ijantimicag.2018.12.009","article-title":"Spiramycin and azithromycin, safe for administration to children, exert antiviral activity against enterovirus A71 in vitro and in vivo","volume":"53","author":"Zeng","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b0955","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.bioorg.2021.105016_b0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104228","article-title":"In Vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect","volume":"145","author":"Andreani","year":"2020","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.bioorg.2021.105016_b0965","unstructured":"The Carrimycin Clinical Trial in China: An Obscure Drug Targeting Upper Respiratory Infection https:\/\/trialsitenews.com\/the-carrimycin-clinical-trial-in-china-an-obscure-drug-targeting-upper-respiratory-infection\/ (accessed Mar 10, 2021)."},{"key":"10.1016\/j.bioorg.2021.105016_b0970","unstructured":"FDA Approves Phase III Trial of Synthetic Biological COVID-19 Treatment. European Pharmaceutical Review."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105016_b0975","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9394(14)70277-6","article-title":"Ocular symptoms and signs associated with suramin sodium treatment for metastatic cancer of the prostate","volume":"121","author":"Hemady","year":"1996","journal-title":"Am. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b0980","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s43141-020-00055-5","article-title":"Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?","volume":"18","author":"Mahmoud","year":"2020","journal-title":"J Genet Eng Biotechnol"},{"key":"10.1016\/j.bioorg.2021.105016_b0985","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2014.11.010","article-title":"A screen of the NIH clinical collection small molecule library identifies potential anti-coronavirus drugs","volume":"114","author":"Cao","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bioorg.2021.105016_b0990","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104874","article-title":"Nitazoxanide\/azithromycin combination for COVID-19: a suggested new protocol for early management","volume":"157","author":"Kelleni","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b0995","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S2055-6640(20)30017-0","article-title":"Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19","volume":"6","author":"Pepperrell","year":"2020","journal-title":"J Virus Erad"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b1000","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1473-3099(06)70361-9","article-title":"New insights into the antiviral effects of chloroquine","volume":"6","author":"Savarino","year":"2006","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b1005","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/cr.2012.165","article-title":"Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model","volume":"23","author":"Yan","year":"2013","journal-title":"Cell Res"},{"key":"10.1016\/j.bioorg.2021.105016_b1010","doi-asserted-by":"crossref","DOI":"10.1186\/1743-422X-2-69","article-title":"chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b1015","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.293","article-title":"targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases","volume":"5","author":"Al-Bari","year":"2017","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b1020","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbrc.2004.08.085","article-title":"In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine","volume":"323","author":"Keyaerts","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.bioorg.2021.105016_b1025","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of middle east respiratory syndrome coronavirus replication in cell culture","volume":"58","author":"de Wilde","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105016_b1030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105980","article-title":"Chloroquine as a prophylactic agent against COVID-19?","volume":"55","author":"Gendrot","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b1035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"issue":"15","key":"10.1016\/j.bioorg.2021.105016_b1040","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bioorg.2021.105016_b1045","unstructured":"D_Piperaquine.Pdf."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105016_b1050","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1473-3099(15)00487-9","article-title":"Dihydroartemisinin-piperaquine resistance in plasmodium falciparum malaria in cambodia: a multisite prospective cohort study","volume":"16","author":"Amaratunga","year":"2016","journal-title":"Lancet. Infect. Dis"},{"key":"10.1016\/j.bioorg.2021.105016_b1055","article-title":"Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists","volume":"m1086","author":"Day","year":"2020","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.bioorg.2021.105016_b1060","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b1065","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000375362","article-title":"Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats","volume":"131","author":"Qiao","year":"2015","journal-title":"Cardiology"},{"issue":"4","key":"10.1016\/j.bioorg.2021.105016_b1070","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.bbrc.2004.05.114","article-title":"Susceptibility to SARS coronavirus s protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor","volume":"319","author":"Hofmann","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bioorg.2021.105016_b1075","article-title":"Identifying Common Pharmacotherapies Associated with Reduced COVID-19 Morbidity Using Electronic Health Records","author":"Castro","year":"2020","journal-title":"Infectious Diseases (except HIV\/AIDS)"},{"key":"10.1016\/j.bioorg.2021.105016_b1080","article-title":"Celebrex Adjuvant Therapy on COVID-19: An Experimental Study","author":"Hong","year":"2020","journal-title":"Public and Global Health"},{"issue":"8","key":"10.1016\/j.bioorg.2021.105016_b1085","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1177\/135965350601100803","article-title":"Indomethacin has a potent antiviral activity against SARS coronavirus","volume":"11","author":"Amici","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bioorg.2021.105016_b1090","doi-asserted-by":"crossref","unstructured":"T. Xu, X. Gao, Z. Wu, D.W. Selinger, Z. Zhou, Indomethacin Has a Potent Antiviral Activity against SARS CoV-2 in Vitro and Canine Coronavirus in Vivo; preprint; Microbiology, 2020. https:\/\/doi.org\/10.1101\/2020.04.01.017624.","DOI":"10.1101\/2020.04.01.017624"},{"issue":"3","key":"10.1016\/j.bioorg.2021.105016_b1095","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10928-020-09690-4","article-title":"Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2","volume":"47","author":"Gomeni","year":"2020","journal-title":"J. Pharmacokinet Pharmacodyn"},{"issue":"11","key":"10.1016\/j.bioorg.2021.105016_b1100","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.3390\/ijms21113793","article-title":"Prediction of novel inhibitors of the main protease (M-pro) of SARS-CoV-2 through consensus docking and drug reposition","volume":"21","author":"Gimeno","year":"2020","journal-title":"IJMS"},{"key":"10.1016\/j.bioorg.2021.105016_b1105","article-title":"COVID-19 severity in obese patients: potential mechanisms and molecular targets for clinical intervention","volume":"S1871403X21000041","author":"Sharma","year":"2021","journal-title":"Obesity Res. Clin. Pract."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b1110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.rdc.2015.08.002","article-title":"Corticosteroids","volume":"42","author":"Ramamoorthy","year":"2016","journal-title":"Rheumatic Disease Clinics of North America"},{"issue":"5","key":"10.1016\/j.bioorg.2021.105016_b1115","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"issue":"9","key":"10.1016\/j.bioorg.2021.105016_b1120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman","year":"2006","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.bioorg.2021.105016_b1125","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","article-title":"Corticosteroid therapy for critically Ill patients with middle east respiratory syndrome","volume":"197","author":"Arabi","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"7","key":"10.1016\/j.bioorg.2021.105016_b1130","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Int. Med."},{"issue":"8","key":"10.1016\/j.bioorg.2021.105016_b1135","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with Covid-19","volume":"384","author":"The RECOVERY Collaborative Group","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b1140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106080","article-title":"COVID-19 treatment: close to a cure? a rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2)","volume":"56","author":"Song","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"12","key":"10.1016\/j.bioorg.2021.105016_b1145","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s40265-014-0264-y","article-title":"Fingolimod: a review of its use in relapsing-remitting multiple sclerosis","volume":"74","author":"Sanford","year":"2014","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.bioorg.2021.105016_b1150","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ahj.2014.06.028","article-title":"Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications","volume":"168","author":"Camm","year":"2014","journal-title":"Am. Heart J."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105016_b1155","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1007\/s10753-014-9943-9","article-title":"Anti-inflammatory effect of thalidomide on H1N1 influenza virus-induced pulmonary injury in mice","volume":"37","author":"Zhu","year":"2014","journal-title":"Inflammation"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b1160","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.35","article-title":"Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical coronavirus disease 2019","volume":"10","author":"Chen","year":"2020","journal-title":"Clin. Translat. Med."},{"key":"10.1016\/j.bioorg.2021.105016_b1165","series-title":"Chemotherapeutic Strategy with Synbiotics, Thalidomide and Celecoxib for Severe COVID-19 Pneumonia","author":"Hada","year":"2020"},{"key":"10.1016\/j.bioorg.2021.105016_b1170","article-title":"Immunoglobulins in the Treatment of COVID-19 Infection","volume":"216","author":"Nguyen","year":"2020","journal-title":"Proceed with Caution! Clinical Immunology (Orlando, Fla.)"},{"issue":"12","key":"10.1016\/j.bioorg.2021.105016_b1175","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1159\/000512727","article-title":"Intravenous immunoglobulin for the treatment of COVID-19: a promising tool","volume":"99","author":"Tzilas","year":"2020","journal-title":"Respiration"},{"key":"10.1016\/j.bioorg.2021.105016_b1180","doi-asserted-by":"crossref","unstructured":"J.J. Graber, S. Dhib-Jalbut, Interferons, in: Encyclopedia of the Neurological Sciences; Elsevier, 2014; pp 718\u2013723. https:\/\/doi.org\/10.1016\/B978-0-12-385157-4.00182-2.","DOI":"10.1016\/B978-0-12-385157-4.00182-2"},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b1185","first-page":"16","article-title":"The role of interferon therapy in hepatitis B","volume":"6","author":"Cooksley","year":"2004","journal-title":"MedGenMed"},{"issue":"33","key":"10.1016\/j.bioorg.2021.105016_b1190","article-title":"Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: A rapid and systematic review","volume":"4","author":"Shepherd; Waugh; Hewitson","year":"2000","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.bioorg.2021.105016_b1195","first-page":"369","article-title":"Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis","volume":"3","author":"Paolicelli","year":"2009","journal-title":"Biologics"},{"key":"10.1016\/j.bioorg.2021.105016_b1200","unstructured":"Interferons https:\/\/www.COVID-19treatmentguidelines.nih.gov\/immunomodulators\/interferons\/ (accessed Mar 11, 2021)."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b1205","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S2213-2600(20)30523-3","article-title":"Nebulised interferon beta-1a for patients with COVID-19","volume":"9","author":"Peiffer-Smadja","year":"2021","journal-title":"Lancet Respirat. Med."},{"issue":"15","key":"10.1016\/j.bioorg.2021.105016_b1210","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"JNCI J. Natl. Can. Inst."},{"key":"10.1016\/j.bioorg.2021.105016_b1215","doi-asserted-by":"crossref","DOI":"10.14744\/ejmo.2020.67429","article-title":"Interleukin-2 Level for Normal People and COVID-19 Infection: Is It Our Concern Is COVID-19 Infection or Inreleukin-2 Level before the Infection?","author":"Yazan","year":"2020","journal-title":"EJMO"},{"issue":"6347","key":"10.1016\/j.bioorg.2021.105016_b1220","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/353858a0","article-title":"Lnterleukin-2 programs mouse \u0391\u03b2 T lymphocytes for apoptosis","volume":"353","author":"Lenardo","year":"1991","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bioorg.2021.105016_b1225","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"issue":"04","key":"10.1016\/j.bioorg.2021.105016_b1230","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1142\/S0192415X07005077","article-title":"The efficacy of chinese medicine for SARS: a review of chinese publications after the crisis","volume":"35","author":"Leung","year":"2007","journal-title":"Am. J. Chin. Med."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105016_b1235","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1089\/acm.2004.10.1041","article-title":"Chinese herbal medicine for severe acute respiratory syndrome: a systematic review and meta-analysis","volume":"10","author":"Liu","year":"2004","journal-title":"J. Alternative Complementary Med."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b1240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2012.10.006","article-title":"Traditional chinese herbal medicine as a source of molecules with antiviral activity","volume":"97","author":"Li","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bioorg.2021.105016_b1245","article-title":"Traditional Chinese medicine for COVID-19 treatment","volume":"155","author":"Ren","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b1250","article-title":"Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines","volume":"9","author":"Ang","year":"2020","journal-title":"Integrat. Med. Res."},{"key":"10.1016\/j.bioorg.2021.105016_b1255","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104761","article-title":"Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)","volume":"156","author":"Runfeng","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105016_b1260","doi-asserted-by":"crossref","first-page":"417","DOI":"10.14719\/pst.2020.7.3.831","article-title":"A review on scope of immuno-modulatory drugs in ayurveda for prevention and treatment of Covid-19","volume":"7","author":"Niraj","year":"2020","journal-title":"Plant Sci. Today"},{"key":"10.1016\/j.bioorg.2021.105016_b1265","unstructured":"Formal launch of the inter-disciplinary studies involving AYUSH interventions for COVID 19 situation pib.gov.in\/Pressreleaseshare.aspx?PRID=1621492 (accessed Mar 11, 2021)."},{"key":"10.1016\/j.bioorg.2021.105016_b1270","unstructured":"CTRI http:\/\/ctri.nic.in\/Clinicaltrials\/showallp.php?mid1=42899&EncHid=&userName=024882 (accessed Mar 11, 2021)."},{"key":"10.1016\/j.bioorg.2021.105016_b1275","unstructured":"Ayush 64.Pdf. http:\/\/www.ccras.nic.in\/sites\/default\/files\/viewpdf\/IEC_Communication\/Ayush%2064.pdf (accessed Mar 11, 2021)."},{"key":"10.1016\/j.bioorg.2021.105016_b1280","unstructured":"CTRI http:\/\/ctri.nic.in\/Clinicaltrials\/showallp.php?mid1=43665&EncHid=&userName=025332 (accessed Mar 11, 2021)."},{"key":"10.1016\/j.bioorg.2021.105016_b1285","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jep.2018.02.040","article-title":"Effects of indole alkaloids from leaf of alstonia scholaris on post-infectious cough in mice","volume":"218","author":"Zhao","year":"2018","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bioorg.2021.105016_b1290","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jep.2015.12.022","article-title":"Effect of total alkaloids from alstonia scholaris on airway inflammation in rats","volume":"178","author":"Zhao","year":"2016","journal-title":"J. Ethnopharmacol."},{"issue":"8","key":"10.1016\/j.bioorg.2021.105016_b1295","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/ptr.5109","article-title":"Expression of pro-inflammatory interleukin-8 is reduced by ayurvedic decoctions: INDIAN DECOCTIONS REDUCE IL-8 EXPRESSION","volume":"28","author":"Guerrini","year":"2014","journal-title":"Phytother. Res."},{"issue":"4","key":"10.1016\/j.bioorg.2021.105016_b1300","doi-asserted-by":"crossref","first-page":"322","DOI":"10.4103\/0255-0857.43561","article-title":"Antiviral activity of the Indian medicinal plant extract, Swertia Chirata against herpes simplex viruses: a study by in-vitro and molecular approach","volume":"26","author":"Gopalkrishna","year":"2008","journal-title":"Indian J Med Microbiol"},{"issue":"4","key":"10.1016\/j.bioorg.2021.105016_b1305","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jbiosc.2019.04.006","article-title":"Viral protein R inhibitors from swertia chirata of Myanmar","volume":"128","author":"Woo","year":"2019","journal-title":"J. Biosci. Bioeng."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105016_b1310","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/13880200903085474","article-title":"In Vivo immunomodulatory activities of the aqueous extract of bonduc nut Caesalpinia Bonducella seeds","volume":"48","author":"Shukla","year":"2010","journal-title":"Pharm. Biol."},{"issue":"4 Suppl","key":"10.1016\/j.bioorg.2021.105016_b1315","first-page":"1517","article-title":"In vivo anti-inflammatory, analgesic and antipyretic activities of a medicinal plant, caesalpinia bonducella F","volume":"28","author":"Shukla","year":"2015","journal-title":"Pak J Pharm Sci"},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b1320","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.fct.2009.09.015","article-title":"Studies on anti-inflammatory, antipyretic and analgesic properties of caesalpinia bonducella F. Seed oil in experimental animal models","volume":"48","author":"Shukla","year":"2010","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.bioorg.2021.105016_b1325","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112571","article-title":"A comprehensive insight on the recent development of cyclic dependent kinase inhibitors as anticancer agents","volume":"203","author":"Marak","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105016_b1330","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1038\/s41467-019-11429-w","article-title":"Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations","volume":"10","author":"de Wispelaere","year":"2019","journal-title":"Nat Commun"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682100393X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682100393X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:21:16Z","timestamp":1758615676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682100393X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":266,"alternative-id":["S004520682100393X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105016","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential drug development and therapeutic approaches for clinical intervention in COVID-19","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105016"}}